For: | Ladino M, Pedraza F, Roth D. Opportunities for treatment of the hepatitis C virus-infected patient with chronic kidney disease. World J Hepatol 2017; 9(19): 833-839 [PMID: 28740594 DOI: 10.4254/wjh.v9.i19.833] |
---|---|
URL: | https://www.wjgnet.com/1948-5182/full/v9/i19/833.htm |
Number | Citing Articles |
1 |
Zana Sidiq Mohammed Saleem, Ibrahim A Naqid, Nawfal R Hussein, Sidra Jalal Mohammad, Jajeen Shaaban Noaman, Rajeen Salih Haji, Vin Ahmed Haji, Zainnab Muhsin Hussein, Piran Hussamaldin Mohammed. The Prevalence of Hepatitis B and C Virus in Patients With End-Stage Kidney Disease on Regular Hemodialysis in Duhok, Iraq: A Brief Report. Avicenna Journal of Clinical Microbiology and Infection 2020; 7(1): 31 doi: 10.34172/ajcmi.2020.06
|
2 |
Chen-Hua Liu, Jia-Horng Kao. Pan-genotypic direct-acting antivirals for patients with hepatitis C virus infection and chronic kidney disease stage 4 or 5. Hepatology International 2022; 16(5): 1001 doi: 10.1007/s12072-022-10390-z
|
3 |
Chen-Hua Liu, Jou-Wei Lin, Chun-Jen Liu, Tung-Hung Su, Jo-Hsuan Wu, Tai-Chung Tseng, Pei-Jer Chen, Jia-Horng Kao. Long-term Evolution of Estimated Glomerular Filtration Rate in Patients With Antiviral Treatment for Hepatitis C Virus Infection. Clinical Gastroenterology and Hepatology 2023; 21(2): 424 doi: 10.1016/j.cgh.2022.01.050
|
4 |
Fernanda Bellini Lunardi MICHELS, Ana Cristina de Castro AMARAL, Roberto José de CARVALHO-FILHO, Gustavo de Almeida VIEIRA, Ana Lucia da Silva SOUZA, Maria Lucia Gomes FERRAZ. HEPATITIS C TREATMENT OF RENAL TRANSPLANT AND CHRONIC KIDNEY DISEASE PATIENTS: EFFICACY AND SAFETY OF DIRECT-ACTING ANTIVIRAL REGIMENS CONTAINING SOFOSBUVIR. Arquivos de Gastroenterologia 2020; 57(1): 45 doi: 10.1590/s0004-2803.202000000-09
|
5 |
Wei Liu, Xiwen Jiang, Yue Liu, Qingsong Ma. Bioinformatics Analysis of Quantitative PCR and Reverse Transcription PCR in Detecting HCV RNA. Current Bioinformatics 2019; 14(5): 400 doi: 10.2174/1574893613666180703103328
|
6 |
Marco Ladino, David Roth. Hepatitis C Virus Infection in ESKD Patients. Clinical Journal of the American Society of Nephrology 2018; 13(11): 1735 doi: 10.2215/CJN.03700318
|
7 |
Chen‐Hua Liu, Cheng‐Yuan Peng, Wei‐Yu Kao, Sheng‐Shun Yang, Yu‐Lueng Shih, Chin‐Lin Lin, Meng‐Kun Tsai, Chih‐Yuan Lee, Chun‐Chao Chang, Jo‐Hsuan Wu, Chun‐Jen Liu, Tung‐Hung Su, Tai‐Chung Tseng, Pei‐Jer Chen, Jia‐Horng Kao. Hepatitis C virus reinfection in patients on haemodialysis after achieving sustained virologic response with antiviral treatment. Alimentary Pharmacology & Therapeutics 2022; 55(4): 434 doi: 10.1111/apt.16697
|
8 |
Javier Pagan, Marco Ladino, David Roth. Treating hepatitis C virus in dialysis patients: How, when, and why?. Seminars in Dialysis 2019; 32(2): 152 doi: 10.1111/sdi.12764
|
9 |
Adriana Dejman, Marco A. Ladino, David Roth. Treatment and management options for the hepatitis C virus infected kidney transplant candidate. Hemodialysis International 2018; 22(S1) doi: 10.1111/hdi.12646
|
10 |
Yi-Chun Chen, Chung-Yi Li, Shiang-Jiun Tsai, Yen-Chun Chen. Anti-hepatitis C virus therapy in chronic kidney disease patients improves long-term renal and patient survivals. World Journal of Clinical Cases 2019; 7(11): 1270-1281 doi: 10.12998/wjcc.v7.i11.1270
|
11 |
Chen-Hua Liu, Chi-Yi Chen, Wei-Wen Su, Kuo-Chih Tseng, Ching-Chu Lo, Chun-Jen Liu, Jyh-Jou Chen, Cheng-Yuan Peng, Yu-Lueng Shih, Sheng-Shun Yang, Chia-Sheng Huang, Ke-Jhang Huang, Chi-Yang Chang, Ming-Chang Tsai, Wei-Yu Kao, Yo-Jen Fang, Po-Yueh Chen, Pei-Yuan Su, Chih-Wei Tseng, Jow-Jyh Huang, Pei-Lun Lee, Hsueh-Chou Lai, Tsai-Yuan Hsieh, Chung-Hsin Chang, Yi-Jie Huang, Fu-Jen Lee, Chun-Chao Chang, Jia-Horng Kao. Sofosbuvir/velpatasvir with or without low-dose ribavirin for patients with chronic hepatitis C virus infection and severe renal impairment. Gut 2022; 71(1): 176 doi: 10.1136/gutjnl-2020-323569
|